These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 39057168)
1. Temozolomide (TMZ) in the Treatment of Glioblastoma Multiforme-A Literature Review and Clinical Outcomes. Jezierzański M; Nafalska N; Stopyra M; Furgoł T; Miciak M; Kabut J; Gisterek-Grocholska I Curr Oncol; 2024 Jul; 31(7):3994-4002. PubMed ID: 39057168 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors. Birol Sarica F; Tufan K; Cekinmez M; Sen O; Cem Onal H; Mertsoylu H; Topkan E; Pehlivan B; Erdogan B; Nur Altinors M J Neurosurg Sci; 2010 Mar; 54(1):7-19. PubMed ID: 20436394 [TBL] [Abstract][Full Text] [Related]
3. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme. Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406 [TBL] [Abstract][Full Text] [Related]
4. Effect of long-term adjuvant temozolomide chemotherapy on primary glioblastoma patient survival. Huang B; Yu Z; Liang R BMC Neurol; 2021 Nov; 21(1):424. PubMed ID: 34724914 [TBL] [Abstract][Full Text] [Related]
5. The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma. Sher DJ; Henson JW; Avutu B; Hochberg FH; Batchelor TT; Martuza RL; Barker FG; Loeffler JS; Chakravarti A J Neurooncol; 2008 May; 88(1):43-50. PubMed ID: 18231723 [TBL] [Abstract][Full Text] [Related]
6. Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme. Gainer JL; Sheehan JP; Larner JM; Jones DR J Neurosurg; 2017 Feb; 126(2):460-466. PubMed ID: 27177177 [TBL] [Abstract][Full Text] [Related]
7. Bone marrow response as a potential biomarker of outcomes in glioblastoma patients. Vaios EJ; Nahed BV; Muzikansky A; Fathi AT; Dietrich J J Neurosurg; 2017 Jul; 127(1):132-138. PubMed ID: 27739940 [TBL] [Abstract][Full Text] [Related]
8. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles. Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389 [TBL] [Abstract][Full Text] [Related]
9. Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience. Cao JQ; Fisher BJ; Bauman GS; Megyesi JF; Watling CJ; Macdonald DR J Neurooncol; 2012 Apr; 107(2):395-405. PubMed ID: 22105851 [TBL] [Abstract][Full Text] [Related]
10. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial. Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983 [TBL] [Abstract][Full Text] [Related]
11. Valproic acid-induced amphiregulin secretion confers resistance to temozolomide treatment in human glioma cells. Chen JC; Lee IN; Huang C; Wu YP; Chung CY; Lee MH; Lin MH; Yang JT BMC Cancer; 2019 Aug; 19(1):756. PubMed ID: 31370819 [TBL] [Abstract][Full Text] [Related]
13. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme. Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509 [TBL] [Abstract][Full Text] [Related]
14. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist. Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180 [TBL] [Abstract][Full Text] [Related]
15. Exploring the Functional Roles of Telomere Maintenance 2 in the Tumorigenesis of Glioblastoma Multiforme and Drug Responsiveness to Temozolomide. Feng SW; Wu ZS; Chiu YL; Huang SM Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298208 [TBL] [Abstract][Full Text] [Related]
16. Temozolomide nano enabled medicine: promises made by the nanocarriers in glioblastoma therapy. Yasaswi PS; Shetty K; Yadav KS J Control Release; 2021 Aug; 336():549-571. PubMed ID: 34229001 [TBL] [Abstract][Full Text] [Related]
17. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. McGirt MJ; Than KD; Weingart JD; Chaichana KL; Attenello FJ; Olivi A; Laterra J; Kleinberg LR; Grossman SA; Brem H; Quiñones-Hinojosa A J Neurosurg; 2009 Mar; 110(3):583-8. PubMed ID: 19046047 [TBL] [Abstract][Full Text] [Related]
18. Patterns of recurrence and outcomes of glioblastoma multiforme treated with chemoradiation and adjuvant temozolomide. Faustino AC; Viani GA; Hamamura AC Clinics (Sao Paulo); 2020; 75():e1553. PubMed ID: 32935821 [TBL] [Abstract][Full Text] [Related]